Omalizumab is a recombinant humanized IgG monoclonal antibody. Urticaria, commonly known as “rubella”, is a confined edema of the skin and mucous membranes due to a temporary increase in vascular permeability, i.e., hives. This product can improve urticaria, but generally does not eradicate urticaria.
Omalizumab for injection can bind to human immunoglobulin E and prevent human immunoglobulin E from binding to allergens, thus reducing the allergic reaction of urticaria and improving the symptoms of urticaria. However, most patients cannot find the exact cause, which makes it difficult to cure and prone to recurrent attacks.
Adverse reactions to this product include headache, swelling at the injection site, pain, erythema, itching and so on. It is forbidden for those who have allergic reaction to this product.
Urticaria patients should consult the doctor in time, under the guidance of the doctor reasonable use of medication, do not unauthorized use of drugs.